## JBL: Jabil Inc. - XLK: Technology

### Executive Summary

No thesis match: MRS_10 3.0% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($218.14)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. Clarius Group LLC Reduces Position in Apple Inc. $AAPL**
- Source: MarketBeat | 20251229T085101 | Neutral | Relevance: 65%
- Clarius Group LLC decreased its stake in Apple Inc. by 24.3%, selling 36,390 shares and retaining 113,376 shares valued at approximately $28.87 million, comprising 1.7% of its portfolio. This reduction follows significant insider selling, including CEO Tim Cook's sale of 129,963 shares. Despite the reduction, Apple reported strong quarterly results and holds a "Moderate Buy" analyst rating with a target price of $283.92.

**2. UFP Technologies Is Growing Fast, Even If Its Stock Isnâ€™t**
- Source: Finimize | 20251228T210905 | Neutral | Relevance: 64%
- UFP Technologies (UFPT), a specialist in medical device manufacturing, is expanding rapidly due to increased outsourcing demand and strategic acquisitions, yet its stock has underperformed, trading at a discount. Despite strong growth prospects, efficient capital use, and healthy cash flow, UFPT faces risks from customer concentration, regulatory hurdles, and potential margin pressures. The company presents a potentially attractive opportunity for long-term investors interested in medical device outsourcing, despite its recent stock performance.

**3. Apple Inc. $AAPL Stock Position Trimmed by WestHill Financial Advisors Inc.**
- Source: MarketBeat | 20251229T130246 | Neutral | Relevance: 64%
- WestHill Financial Advisors Inc. reduced its stake in Apple Inc. ($AAPL) by 4.9%, selling 2,156 shares to hold 41,971 shares valued at $10.687 million, making Apple its 10th largest holding. Concurrently, Apple CEO Tim Cook and SVP Deirdre O'Brien also sold significant amounts of company stock. Despite insider selling, large institutions like Vanguard and State Street increased their positions, and Apple reported strong quarterly EPS, while analysts maintain a "Moderate Buy" rating with an average target price of $283.92.

**4. Apple Inc. $AAPL Shares Sold by Congress Asset Management Co.**
- Source: MarketBeat | 20251227T085427 | Somewhat-Bullish | Relevance: 63%
- Congress Asset Management Co. reduced its stake in Apple Inc. by 0.5%, selling 7,189 shares and now holding 1,414,488 shares valued at approximately $360.17 million. Despite this, Apple remains their second-largest position, while other institutional investors like Vanguard and State Street increased their holdings. Analysts maintain a "Moderate Buy" rating with a consensus price target of $283.92, although company insiders sold 228,052 shares worth about $58.6 million in the last quarter.

**5. Apple Inc. $AAPL Holdings Decreased by Generali Investments CEE investicni spolecnost a.s.**
- Source: MarketBeat | 20251229T100817 | Neutral | Relevance: 63%
- Generali Investments CEE investicni spolecnost a.s. reduced its holdings in Apple Inc. by 8.1% in the third quarter, while other institutional investors like Vanguard Group Inc. and State Street Corp increased their stakes. Company insiders sold shares totaling approximately $58.6 million in the last quarter. Analyst sentiment remains mixed-to-positive, with an average "Moderate Buy" rating and a target price of $283.92, supported by recent legal wins and new AI model releases despite concerns about Apple's position in generative AI.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 4, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-18 | JP Morgan | $270 | $260 | +4% |
| 2025-12-18 | Barclays | $283 | $267 | +6% |
| 2025-12-18 | UBS | $244 | $239 | +2% |
| 2025-12-10 | B of A Securiti | $262 | $255 | +3% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-18 | JP Morgan | main | Overweight |
| 2025-12-18 | Barclays | main | Overweight |
| 2025-12-18 | UBS | main | Neutral |
| 2025-12-10 | B of A Securiti | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 7 ($0.00M) |
| Sells | 50 ($12.50M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 48.6% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 6 |

**Top Holders:**
- Vanguard Group Inc: 12.3% (-0.1%)
- Blackrock Inc.: 9.0% (+2.1%)
- Texas Yale Capital C: 6.0% (-0.1%)
- State Street Corpora: 4.9% (+0.7%)
- Wellington Managemen: 4.1% (-30.7%)

### Key Risks

1. Heavy insider selling: $13M sold (50 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 4 raises (avg +4%) could attract flows.
- Momentum building: MRS_10 improving +1.0% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 0.91 indicates undervaluation relative to growth. Quality metrics strong (ROE 48%). Insider selling cluster ($12.5M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 6 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $25.1B |
| Beta | 1.26 |
| 52W Range | $108.66 - $237.14 |
| Short Interest | 4.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.91 |
| Forward P/E | 17.3 |
| Current P/E | 20.2 |
| YoY Growth | 16.5% |
| EPS Direction | RISING |

### Technicals

MRS_10 strengthening from 1.9% to 3.0% (+1.0% in 5 days), confirming momentum buildup. Below STRENGTH zone by 0.0pp (needs >3.0% for momentum thesis). MRS_5 at 0.6% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (1.28), confirming momentum. OFD pattern: +SUL (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 2.95% (CS: 98) | Neutral |
| RSI_14 | 63.6 | Neutral |
| MACD Histogram | 1.28 | Bullish |
| vs SMA20 | 1.049x | Above |
| vs SMA50 | 1.094x | Above |
| vs SMA200 | 1.209x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $234.92
- **Stop Loss:** $218.14 (7.1% risk)
- **Target:** $251.70 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 68
- **Position Value:** $15,974.56
- **Portfolio %:** 15.97%
- **Risk Dollars:** $1,150.00
- **Risk Per Trade:** 1.15%
- **Modifiers:** L1 115% | L2 100% | Combined 1.15x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.15x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with selective risk appetite and defensive rotation. VIX at 14.2 (2nd percentile) signals low volatility, while positive yield curve (+58bps) and stable economic indicators support continued expansion. Market breadth at 58.7% shows decent participation, but rotation into defensive names and Fed liquidity concerns warrant measured positioning.*

### Earnings

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q4 | $2.73 | $2.85 | +4.4% |
| 2025Q3 | $2.95 | $3.29 | +11.7% |
| 2025Q2 | $2.32 | $2.55 | +9.8% |
| 2025Q1 | $1.83 | $1.94 | +6.2% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_10*